Oaktree Acquisition Corp. III Life Sciences

What they do

Oaktree Acquisition Corp. III Life Sciences is a Cayman Islands exempted company formed in June 2024 to effect a merger, share exchange, asset acquisition, or similar business combination with one or more businesses. To date, it has only performed organizational activities, IPO-related activities, and its search for an initial business combination; it has generated no operating revenues. The company intends to focus on North American, British, or European companies in biopharmaceuticals, medical devices, diagnostics, and specialized healthcare services, leveraging the Oaktree platform's investment experience. No specific business combination target has been selected.

Revenue drivers

• None — The company has no operating revenues; it does not expect to generate any until it completes an initial business combination.

Recent performance

For the year ended 2025, the company reported net income of $7.3 million and negative operating cash flow of $-422,079. As of June 30, 2026, total assets were $206.5 million, total liabilities were $8.7 million, and shareholder equity was negative at $-7.5 million. Cash and equivalents stood at $1.2 million. The company has not yet consummated a business combination.

Strategy

The company's strategy is to identify and acquire a business in healthcare or healthcare-related industries, focusing on North America, UK, and Europe. It plans to capitalize on Oaktree's global investment platform, which includes approximately $223 billion in AUM as of December 31, 2025, and its prior SPAC de-SPACs with Hims & Hers Health and Alvotech. Management intends to use its operational, diligence, and capital raising expertise to effect a business combination and position the target for long-term success. The company may pursue transactions where existing shareholders hold a minority stake post-combination.

Risks

• No operating history — The company has no operating history and no revenues, giving investors no basis to evaluate its ability to achieve its business objective.
• Target selection risk — Inability to select an appropriate target business or businesses could prevent the completion of an initial business combination.
• Redemption risk — Public shareholders may redeem their shares for cash, which could reduce trust account funds and make the company unattractive to potential targets.
• Geopolitical and economic uncertainty — General economic and political conditions, including recessions, interest rates, geopolitical conflicts, and trade policy changes, could impede the ability to complete a business combination.

Outlook

Management has not provided a specific timeline for selecting or completing a business combination. The forward-looking statements in the filings indicate continuing efforts to search for a target, but with no assurance of success. The company expects to incur no operating revenues until a combination is consummated. Key risks remain around selection, financing, and shareholder redemptions.